Roundtable Discussion: Overcoming Anatomical Barriers to Improve Efficacy in CIDP: Targeting the Spine to Unlock Full Disease Control
- Evaluating the limited spinal and brain penetration of biologics and questioning whether partial efficacy in CIDP reflects anatomical inaccessibility rather than target irrelevance
- Comparing small molecule approaches, acknowledging that small molecules are uniquely capable of accessing central nervous system or spinal tissues to assess whether modality selection could unlock improved disease modification in CIDP
- Aligning anatomical access considerations with translational modelling, ensuring that preclinical systems reflect the compartments drugs must reach to improve the predictive value of translational research in peripheral neuropathies